Beutel Bernd, Daniliuc Constantin G, Riemann Burkhard, Schäfers Michael, Haufe Günter
Organisch-Chemisches Institut, Westfälische Wilhelms-Universität, Corrensstr. 40, 48149 Münster, Germany.
Klinik für Nuklearmedizin, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.
Bioorg Med Chem. 2016 Feb 15;24(4):902-9. doi: 10.1016/j.bmc.2016.01.017. Epub 2016 Jan 9.
Fluorine-containing inhibitors of matrix metalloproteinases (MMPs) can serve as lead structures for the development of (18)F-labeled radioligands. These compounds might be useful as non-invasive imaging probes to characterize pathologies associated with increased MMP activity. Results with a series of fluorinated analogs of a known biphenyl sulfonamide inhibitor have shown that fluorine can be incorporated into two different positions of the molecular scaffold without significant loss of potency in the nanomolar range. Additionally, the potential of a hitherto unknown fluorinated tertiary sulfonamide as MMP inhibitor has been demonstrated.
含氟基质金属蛋白酶(MMPs)抑制剂可作为开发(18)F标记放射性配体的先导结构。这些化合物可能作为非侵入性成像探针,用于表征与MMP活性增加相关的病理情况。一系列已知联苯磺酰胺抑制剂的氟化类似物的研究结果表明,氟可以引入分子支架的两个不同位置,而在纳摩尔范围内不会显著丧失活性。此外,还证明了一种迄今未知的氟化叔磺酰胺作为MMP抑制剂的潜力。